$SAILIFE

Fundamental: Revenue +3.9% YoY | PAT +18.1% YoY | P/E 73.1x vs sector 54.4x (below own 10Y avg of 93.4x) | Upside 24.3% | Operating Margin 30.7% (+310 bps) | ROCE 18.2% | Rank #4/29 peers | Rating 8.44 Technical: Textbook aggressive uptrend — continuous HH-HL structure | Riding above 5/9/13 EMAs, sitting well clear of 200 EMA— relentless buying interest | RSI 65 — strong momentum, not yet overbought | Minor MACD histogram dip (-0.43) — negligible; price shows zero fatigue Moat: India's fastest-growing CDMO with deep relationships across global innovator pharma — 30%+ operating margins and accelerating capex (fixed assets +20%) signal a business scaling into a structurally higher-margin discovery services mix rarely achieved by Indian API/CDMO peers. View: Top-4 in pharma midcap segment, trading below its own historical P/E average despite a 60% one-year return — the price action is textbook momentum with no signs of exhaustion, and the CDMO structural tailwind (China+1, innovator outsourcing) makes every dip a potential accumulation opportunity.